Table of Contents

1 Study Coverage

• 1.1 Antidiabetic Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Antidiabetic Drug Market Size Growth Rate by Product
  • 1.4.2 Alpha-Glucosidase Inhibitors
  • 1.4.3 Biguanides, Sulphonylureas
  • 1.4.4 Glp-1 Agonist
  • 1.4.5 Meglitinides
  • 1.4.6 Dpp-4 Inhibitors
  • 1.4.7 Sglt–2
  • 1.4.8 Thiazolodinediones
• 1.5 Market by End User
  • 1.5.1 Global Antidiabetic Drug Market Size Growth Rate by End User
  • 1.5.2 Type I Diabetes
  • 1.5.3 Type II Diabetes
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Antidiabetic Drug Market Size
  • 2.1.1 Global Antidiabetic Drug Revenue 2014-2025
  • 2.1.2 Global Antidiabetic Drug Sales 2014-2025
• 2.2 Antidiabetic Drug Growth Rate by Regions
  • 2.2.1 Global Antidiabetic Drug Sales by Regions
  • 2.2.2 Global Antidiabetic Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Antidiabetic Drug Sales by Manufacturers
  • 3.1.1 Antidiabetic Drug Sales by Manufacturers
  • 3.1.2 Antidiabetic Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Antidiabetic Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Antidiabetic Drug Revenue by Manufacturers
  • 3.2.1 Antidiabetic Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Antidiabetic Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Antidiabetic Drug Price by Manufacturers
• 3.4 Antidiabetic Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Antidiabetic Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Antidiabetic Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Antidiabetic Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Antidiabetic Drug Sales by Product
• 4.2 Global Antidiabetic Drug Revenue by Product
• 4.3 Antidiabetic Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Antidiabetic Drug Breakdown Data by End User

6 North America

• 6.1 North America Antidiabetic Drug by Countries
  • 6.1.1 North America Antidiabetic Drug Sales by Countries
  • 6.1.2 North America Antidiabetic Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Antidiabetic Drug by Product
• 6.3 North America Antidiabetic Drug by End User

7 Europe

• 7.1 Europe Antidiabetic Drug by Countries
  • 7.1.1 Europe Antidiabetic Drug Sales by Countries
  • 7.1.2 Europe Antidiabetic Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Antidiabetic Drug by Product
• 7.3 Europe Antidiabetic Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Antidiabetic Drug by Countries
  • 8.1.1 Asia Pacific Antidiabetic Drug Sales by Countries
  • 8.1.2 Asia Pacific Antidiabetic Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Antidiabetic Drug by Product
• 8.3 Asia Pacific Antidiabetic Drug by End User

9 Central & South America

• 9.1 Central & South America Antidiabetic Drug by Countries
  • 9.1.1 Central & South America Antidiabetic Drug Sales by Countries
  • 9.1.2 Central & South America Antidiabetic Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Antidiabetic Drug by Product
• 9.3 Central & South America Antidiabetic Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Antidiabetic Drug by Countries
  • 10.1.1 Middle East and Africa Antidiabetic Drug Sales by Countries
  • 10.1.2 Middle East and Africa Antidiabetic Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Antidiabetic Drug by Product
• 10.3 Middle East and Africa Antidiabetic Drug by End User

11 Company Profiles

• 11.1 Sanofi-Aventis
  • 11.1.1 Sanofi-Aventis Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Sanofi-Aventis Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Sanofi-Aventis Antidiabetic Drug Products Offered
  • 11.1.5 Sanofi-Aventis Recent Development
• 11.2 Eli Lilly
  • 11.2.1 Eli Lilly Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Eli Lilly Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Eli Lilly Antidiabetic Drug Products Offered
  • 11.2.5 Eli Lilly Recent Development
• 11.3 Oramed
  • 11.3.1 Oramed Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Oramed Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Oramed Antidiabetic Drug Products Offered
  • 11.3.5 Oramed Recent Development
• 11.4 Takeda
  • 11.4.1 Takeda Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Takeda Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Takeda Antidiabetic Drug Products Offered
  • 11.4.5 Takeda Recent Development
• 11.5 Boehringer Ingelheim
  • 11.5.1 Boehringer Ingelheim Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Boehringer Ingelheim Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Boehringer Ingelheim Antidiabetic Drug Products Offered
  • 11.5.5 Boehringer Ingelheim Recent Development
• 11.6 Novo Nordisk
  • 11.6.1 Novo Nordisk Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Novo Nordisk Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Novo Nordisk Antidiabetic Drug Products Offered
  • 11.6.5 Novo Nordisk Recent Development
• 11.7 Halozyme Therapeutics
  • 11.7.1 Halozyme Therapeutics Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Halozyme Therapeutics Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Halozyme Therapeutics Antidiabetic Drug Products Offered
  • 11.7.5 Halozyme Therapeutics Recent Development
• 11.8 Bristol-Myers Squibb
  • 11.8.1 Bristol-Myers Squibb Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Bristol-Myers Squibb Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Bristol-Myers Squibb Antidiabetic Drug Products Offered
  • 11.8.5 Bristol-Myers Squibb Recent Development
• 11.9 Pfizer
  • 11.9.1 Pfizer Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Pfizer Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Pfizer Antidiabetic Drug Products Offered
  • 11.9.5 Pfizer Recent Development
• 11.10 Tonghua Dongbao
  • 11.10.1 Tonghua Dongbao Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Tonghua Dongbao Antidiabetic Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Tonghua Dongbao Antidiabetic Drug Products Offered
  • 11.10.5 Tonghua Dongbao Recent Development
• 11.11 Biocon
• 11.12 Wockhardt

12 Future Forecast

• 12.1 Antidiabetic Drug Market Forecast by Regions
  • 12.1.1 Global Antidiabetic Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Antidiabetic Drug Revenue Forecast by Regions 2019-2025
• 12.2 Antidiabetic Drug Market Forecast by Product
  • 12.2.1 Global Antidiabetic Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Antidiabetic Drug Revenue Forecast by Product 2019-2025
• 12.3 Antidiabetic Drug Market Forecast by End User
• 12.4 North America Antidiabetic Drug Forecast
• 12.5 Europe Antidiabetic Drug Forecast
• 12.6 Asia Pacific Antidiabetic Drug Forecast
• 12.7 Central & South America Antidiabetic Drug Forecast
• 12.8 Middle East and Africa Antidiabetic Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Antidiabetic Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Diabetes mellitus is a kind of chronic comprehensive disease mainly caused by glucose metabolism disorder due to absolute or relative deficiency of insulin or decreased insulin sensitivity of target cells. The occurrence of type 2 diabetes mellitus is a combination of peripheral insulin resistance and β cell dysfunction. the result of. When diabetes patients undergo diet and exercise therapy and diabetes care education, blood glucose control can still not reach the treatment goals, the need for drug treatment-Antidiabetic Drug
The global anti-diabetic drug market is expected to witness significant growth during the forecast period. This growth is attributed due to increasing prevalence of diabetes and rising demand for oral anti-diabetic drugs. In addition, sedentary lifestyle, increasing the percentage of obesity, high-stress levels are considered as a major driving factor for the growth of oral anti-diabetic drugs market. Furthermore, technological advancement and medical reimbursements can also help in fuelling the growth of oral antidiabetic drug market. However, the high cost of drugs is considered as a major restraint for the market. Nonetheless ongoing research and huge market potential can bring growth opportunities for anti-diabetic market within the forecast period.
Based on the class of drug, the global anti-diabetic drug market is segmented into five types: sulfonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors and others. Sulphonylureas segment of oral anti-diabetic drugs market accounted for the largest market share in 2018followed by biguanides derivatives. Sulfonylureas were the largest segment and acquired around 37% of world market share followed by biguanide derivatives in 2018 Sulfonylureas are a class of organic compounds used in medicine and agriculture. They are antidiabetic drugs widely used in the management of type 2 diabetes mellitus. They act by increasing insulin release from the beta cells in the pancreas.
The global Antidiabetic Drug market is valued at 49600 million US$ in 2018 and will reach 96700 million US$ by the end of 2025, growing at a CAGR of 10.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Antidiabetic Drug market based on company, product type, end user and key regions.

This report studies the global market size of Antidiabetic Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Antidiabetic Drug in these regions.
This research report categorizes the global Antidiabetic Drug market by top players/brands, region, type and end user. This report also studies the global Antidiabetic Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sanofi-Aventis
Eli Lilly
Oramed
Takeda
Boehringer Ingelheim
Novo Nordisk
Halozyme Therapeutics
Bristol-Myers Squibb
Pfizer
Tonghua Dongbao
Biocon
Wockhardt

Market size by Product
Alpha-Glucosidase Inhibitors
Biguanides, Sulphonylureas
Glp-1 Agonist
Meglitinides
Dpp-4 Inhibitors
Sglt–2
Thiazolodinediones
Market size by End User
Type I Diabetes
Type II Diabetes

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Antidiabetic Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Antidiabetic Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Antidiabetic Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Antidiabetic Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Antidiabetic Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Antidiabetic Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.